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It has been known for decades that cancer cells have an al-
tered metabolism. As early as the 1920s, Otto Warburg ob-
served that tumor cells consume glucose at a high rate and 
undergo fermentation even in the presence of oxygen (War-
burg et al., 1927). Since then, drugs targeting metabolism 
have transformed the treatment of certain cancers. In the 
1940s, the discovery and application of aminopterin, which 
was later found to target dihydrofolate reductase (DHFR), a 
cytoplasmic enzyme involved in one-carbon folate metabo-
lism, yielded the first remission in a child with acute lympho-
blastic leukemia (Farber et al., 1948). Other folate derivatives, 
such as methotrexate, were later developed. More recently, 
drugs such as 5-fluorouracil and pemetrexed that target thy-
midylate synthetase, another enzyme involved in one-carbon 
folate metabolism, were found to be effective therapies for 
some cancers (Locasale, 2013).
The discovery of germline and somatic mutations that 
alter metabolic proteins in cancer further supports the role of 
altered metabolism in cancer pathogenesis. Mutations in genes 
of the succinate dehydrogenase complex, critical for both the 
tricarboxylic acid (TCA) cycle and electron transport chain, 
have been implicated in the pathogenesis of hereditary para-
gangliomas (Baysal et al., 2000; Niemann and Müller, 2000), 
pheochromocytomas (Astuti et al., 2001), renal cell cancer 
(Vanharanta et al., 2004), and gastrointestinal stromal tumors 
(Janeway et al., 2011; Pantaleo et al., 2011). In addition, muta-
tions in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) 
have been found in subsets of gliomas (Yan et al., 2009; Bren-
nan et al., 2013) and acute myeloid leukemia (AML; Paschka 
et al., 2010; Cancer Genome Atlas Research Network, 2013), 
among other malignancies. Drugs targeting these mutant 
proteins have entered the clinic with some successes in early 
phase trials (Stein et al. 2014. 56th Annual American Hema-
toligical Society Annual Meeting and Exposition. Abstract 
115.). Moreover, as understanding of the metabolic derange-
ments necessary to promote and maintain the malignant state 
continues to expand, so does the list of potential drug tar-
gets. For example, aerobic glycolysis is thought to enable the 
generation of the nucleotides, proteins, and lipids necessary 
to maintain the malignant proliferative state, in part through 
regulation of the glycolytic enzyme pyruvate kinase (Vander 
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Heiden et al., 2010). Additionally, the discovery of the critical 
importance of glycine and serine in cancer metabolism has 
led to a resurgence in interest in better understanding the 
mechanistic relevance of one-carbon folate metabolism (Jain 
et al., 2012; Zhang et al., 2012; Labuschagne et al., 2014; Ye et 
al., 2014; Kim et al., 2015; Maddocks et al., 2016).
Although drugs targeting metabolism, such as metho-
trexate and asparaginase (a drug that reduces the availability 
of asparagine and glutamine), have been critical for the treat-
ment of acute lymphoblastic leukemia, they are not used in 
therapy for AML, a hematopoietic malignancy where cure 
rates are still quite poor despite high-dose cytotoxic chemo-
therapy, including stem cell transplantation. This is especially 
true for patients with subtypes of AML characterized by 
high-risk features, such as the presence of FLT3-ITD muta-
tions. New therapies are urgently needed for the treatment 
of these patients. In this study, we set out to define com-
mon mechanisms critical to the maintenance of AML cells 
to nominate novel, potentially targetable metabolic pathways 
for the treatment of this disease. We integrated gene expres-
sion signatures generated from the treatment of AML cells 
with multiple small molecules known to promote AML dif-
ferentiation and death. Methylenetetrahydrofolate dehydro-
genase 2 (MTH FD2), an NAD+-dependent enzyme with 
dehydrogenase and cyclohydrolase activity, which plays an 
essential role in mitochondrial one-carbon folate metabo-
lism, was prioritized as a target relevant to AML cell growth 
and differentiation. Suppression of MTH FD2 impaired AML 
growth and induced differentiation in vitro and impaired dis-
ease progression in multiple mouse models of AML. Addi-
tionally, FLT3-ITD mutations are a biomarker of response to 
MTH FD2 suppression. Mechanistically, MYC directly reg-
ulates MTH FD2 expression, and suppression of MTH FD2 
leads to marked alteration of the TCA cycle.
RES ULTS
One-carbon folate metabolism is a core pathway altered 
with compounds active in AML cells
We analyzed gene expression signatures of HL-60 cells 
treated with 1,25-dihydroxy Vitamin D3 (Vitamin D), PMA, 
and all-trans retinoic acid (Stegmaier et al., 2004), along with 
gene expression signatures of THP-1 cells treated with the 
BET bromodomain inhibitor JQ1 (Zuber et al., 2011), and 
MV4-11 and MOLM-13 cells treated with the DOT1L 
inhibitor EPZ004777 (Daigle et al., 2011), compounds 
that cause AML differentiation and death. We identified a 
list of genes significantly down-regulated by the individual 
agents (fold change expression ≥ 1.5, P ≤ 0.05, Benjami-
ni-Hochberg False Discovery Rate [FDR(BH)] ≤ 0.05) and 
found a core subset of 198 genes that were robustly down- 
regulated across all five datasets based on the selection cri-
teria mean fold change of expression ≥ 1.5 across all data-
sets and (ii) significant fold change of expression ≥ 1.5 (P 
≤ 0.05, FDR(BH) ≤ 0.05) in at least four out of the five 
datasets (Fig. 1 A and Table S1). We then used this core list 
of genes to probe for enrichment across the Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) curated collection of 
canonical pathways (Kanehisa et al., 2014), available from the 
Molecular Signature Database (MSigDB) v4.0 (Subramanian 
et al., 2005). Three metabolic pathways, One Carbon Pool 
by Folate, Purine Metabolism, and Pyrimidine Metabolism, 
along with five other pathways involved in cell cycle, splic-
ing, and DNA mismatch repair, were significantly enriched 
in the core list of genes (FDR (q value) ≤ 10−4; Fig. 1 B). 
The role of folate-mediated one-carbon metabolism in can-
cer, especially in the mitochondrial compartment, has been 
a subject of renewed interest (Jain et al., 2012; Nilsson et al., 
2014). A recent publication has highlighted the mitochon-
drial enzyme involved in one-carbon folate metabolism, 
MTHFD2, as the most differentially expressed enzyme in 
cancer cells compared with normal cells (Nilsson et al., 2014). 
Indeed, across all five treatments there was down-regulation of 
MTHFD2 expression (Fig. 1 C). We thus focused on the rel-
evance of MTHFD2 to AML growth and maturation. We first 
determined the expression of MTHFD2 across normal my-
eloid differentiation using a publicly available dataset profiling 
the transcriptomes of hematopoietic cells across various stages 
of hematopoietic differentiation (Novershtern et al., 2011). 
MTHFD2 expression was enriched in the myeloid lineage 
during normal hematopoietic differentiation (Fig. 1 D).
MTH FD2 suppression impairs growth and 
promotes AML differentiation
We generated multiple shRNAs targeting MTH FD2 and val-
idated knockdown by Western blot (Fig. 2 A). Two shRNAs, 
shMTH FD2_3 and shMTH FD2_5, led to the greatest and 
most consistent suppression of MTH FD2 by Western blot, 
and we used these two shRNAs in subsequent experiments.
Suppression of MTH FD2 in three human AML cell 
lines caused a decrease in growth (Fig.  2  B) that was also 
observed with Mthfd2 suppression in mouse MLL-AF9 leu-
kemia cells (Fig. 2, C and D). MTH FD2 suppression in non-
cancer cell lines, human embryonic kidney cells 293T, and 
the mouse pro–B cell line Ba/F3, had minimal effect on cell 
growth (Fig. 2 E). MTH FD2 suppression accordingly led to 
a G0/G1 arrest (Fig. 2 F), and the formation of AML col-
onies in methylcellulose was decreased upon suppression of 
MTH FD2 in human AML cell lines (Fig.  2  G), in mouse 
MLL-AF9 AML cells (Fig.  2  H), and in primary AML 
patient samples (Fig. 2 I).
We next evaluated the effects of MTH FD2 suppression 
on differentiation using whole transcriptome profiling. shMTH 
FD2_5 was used to knockdown MTH FD2 in MOLM-14 cells 
and RNA sequencing was performed. Gene sets consistent with 
myeloid maturation were enriched in the transcriptional profil-
ing of MOLM-14 cells with MTH FD2 suppression (Fig. 3 A), 
and gene sets consistent with hematopoietic stem cell signatures 
were repressed (Fig. 3 B). There was up-regulation of well-val-
idated myeloid differentiation genes in the top 50 differentially 
expressed genes (Fig. 3 C). Moreover, MTH FD2 suppression 
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Figure 1. One-carbon folate metabolism is a core pathway altered with AML targeting compounds. (A) Intersection of genes down-regulated 
by five compounds that cause AML death and differentiation: Vitamin D, PMA, ATRA, JQ1, and EPZ004777. Reported is the number of significantly down- 
regulated genes by each agent (DMSO vs. agent: SNR ≥ 1.5; P ≤ 0.05; FDR[BH] ≤ 0.05). The core 198 genes are significantly down-regulated by each of 
the five agents (DMSO vs. agent: average SNR across all conditions ≥ 1.5 and SNR ≥ 1.5 in four out of five conditions). P-values calculated using the per-
mutation test implemented in the comparative marker selection procedure, Gene Pattern v3.8.1. (B) Pathway enrichment analysis across KEGG canonical 
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resulted in morphological changes, such as nuclear condensa-
tion and cytoplasmic ruffling (Fig. 3 D), and the expression of 
surface CD11b (Fig. 3 E), both of which are consistent with 
myeloid maturation. We next evaluated the effects of MTH FD2 
suppression on AML differentiation using our previously pub-
lished 32-gene expression differentiation signature that can be 
measured by ligation-mediated amplification and a fluorescent, 
bead-based detection system (Stegmaier et al., 2004). Suppres-
sion of MTH FD2 resulted in induction of the myeloid differen-
tiation signature in the three evaluated AML cell lines (Fig. 3 F).
pathways showed eight significantly overlapping pathways. P-values calculated using the hypergeometric test for gene set overlapping analysis. (C) Heat 
maps showing expression for genes of one-carbon folate pathway across five treatments with differentiation agents. (D) Expression of MTH FD2 across 
the hematopoietic lineage.
Figure 2. MTH FD2 suppression impairs growth of AML. (A) Western blot evaluating knockdown of MTH FD2 with four unique shRNAs, shMTH FD2_1, 
shMTH FD2_2, shMTH FD2_3, and shMTH FD2_5. Vinculin is used as a loading control. (B) Viability measured by Trypan blue exclusion over a time course with 
MTH FD2-directed shRNA versus control shRNA. Shown are the mean ± SD of three replicates. Data show a representative experiment from at least three 
individual experiments. (C) pLKO.1 constructs expressing hairpins targeting Mthfd2 were used to infect mouse MLL-AF9 leukemia cells, and knockdown was 
confirmed by Western blot analysis. (D) Growth was assessed after Mthfd2 knockdown using an ATP-based assay. Data represent mean ± SD for six repli-
cates. (E) Viability measured by an ATP-based assay over a time course with MTH FD2-directed shRNA versus control shRNA in 293T and Ba/F3 cells. Shown 
are the mean ± SD of 14 replicates. (F) Cell cycle analysis in U937 and MOLM-14 cells 4 d after MTH FD2 suppression. Shown is the mean of three separate 
experiments. (G) Colony formation in methylcellulose assessed 5 d after infection with shRNAs directed against MTH FD2 or a control shRNA in three AML 
cell lines. Data represent mean ± SD of two technical replicates. Data show a representative experiment from at least three individual experiments. *, P < 
0.05 using unpaired Student’s t test with Welch’s correction. (H) Colony formation in methylcellulose was assessed 5 d after infection with shRNAs directed 
against Mthfd2 or a control. Data represent mean ± SD of two technical replicates. Data show a representative experiment of two individual experiments. *, 
P < 0.05 using unpaired Student’s t test with Welch’s correction. (I) Colony formation in methylcellulose in six primary patient samples. Red indicates patient 
sample with FLT3-ITD mutation. Data normalized to shControl for each sample. *, P < 0.05 using Mann-Whitney test.
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Figure 3. MTH FD2 suppression impairs AML differentiation. (A) GSEA plot showing the enrichment of the genes down-regulated by MTH FD2 knock-
down in the DMAP monocyte differentiation signature. P < 0.001, computed using the permutation test for gene set enrichment implemented in the GSEA 
v2.0.14 platform. (B) GSEA plots showing enrichment of embryonic stem cell genes down-regulated with MTH FD2 suppression. P < 0.001, computed using 
the permutation test for gene set enrichment implemented in the GSEA v2.0.14 platform. (C) Heat map showing top 50 out of 229 leading edge genes 
for the shMTH FD2 genome-wide signature with respect to monocyte versus HSC signature from DMAP (SNR ≥ 1.5; P ≤ 0.05; FDR[BH] ≤ 0.05). P-value 
computed using the permutation test implemented in the comparative marker selection procedure, Gene Pattern v3.8.1. Exemplary genes known to be 
up-regulated with myeloid differentiation are highlighted in red. (D) May-Grunwald Giemsa staining of AML cell lines after MTH FD2 knockdown 9 d after 
infection. Bars, 25 µm. Shown are representative images from three different experiments. (E) CD11b staining by flow cytometry after MTH FD2 knockdown 
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MTH FD2 suppression impairs leukemia establishment 
and progression in vivo
In vitro studies are critical for initial target validation, but do 
not completely recapitulate response in a vertebrate organism. 
Currently, there are no commercially available inhibitors of 
MTH FD2. We thus extended testing of MTH FD2-directed 
hairpins to a human AML orthotopic xenograft model. Here, 
U937 cells were labeled with luciferase (U937-LucNeo), in-
fected with vectors bearing MTH FD2-directed shRNAs 
(shMTH FD2_3 and shMTH FD2_5), and selected with pu-
romycin. Knockdown of MTH FD2 was then confirmed by 
Western immunoblotting before injection by tail vein into 
NOD-SCID IL2Rγnull (NSG) mice (Fig. 4 A). Loss of MTH 
FD2 impaired progression of this U937 orthotopic xenograft, 
as measured in vivo by bioluminescence (Fig. 4 A). Addition-
ally, we used an MLL-AF9 mouse leukemia model to test the 
effect of Mthfd2 suppression. Leukemia cells were infected 
with vectors bearing Mthfd2-directed shRNAs (shMthfd2_
A1, shMthfd2_A2, and shMthfd2_A4), and selected with pu-
romycin. Knockdown of Mthfd2 was confirmed by RNA 
expression (Fig. 4 B). Loss of Mthfd2 decreased leukemia bur-
den and prolonged survival in this aggressive mouse leukemia 
model (Fig. 4, C and D).
To study the effects of MTH FD2 suppression after 
the development of AML in vivo, we deployed the doxy-
cycline-inducible miR30 shRNA system directed against 
MTH FD2 using the two constructs that yielded efficient sup-
pression of MTH FD2 (Fig. 4, E and F). U937-LucNeo cells 
bearing the doxycycline-inducible miR30 shRNA directed 
against MTH FD2 were injected into Nude mice. Leukemia 
establishment was confirmed by bioluminescence, and then 
mice were treated with doxycycline and monitored for dis-
ease progression and overall survival. Induction of MTH FD2 
knockdown led to a decrease in leukemia burden and pro-
longed survival compared with control mice (Fig. 4, G and H).
FLT3-ITD is a biomarker of response to MTH FD2 suppression
To identify potential biomarkers of response to MTH FD2 
suppression, we performed single-sample Gene Set Enrich-
ment Analysis (ssGSEA) in two large human primary pa-
tient AML gene expression datasets, TCGA LAML (Cancer 
Genome Atlas Research Network, 2013; 179 tumors) and a 
dataset described in Wouters et al. (2009); 526 tumors); 526 
tumors) for enrichment across the collection of 186 canonical 
KEGG pathways. Consensus hierarchical clustering of sam-
ples in the ssGSEA projections identified a robust subset of 
n = 67 (out of 179) patients in the TCGA LAML data and n 
= 145 (out of 526) patients in the Wouters et al. (2009) data 
that showed enrichment in gene expression of members of 
the one-carbon folate pathway (Fig.  5 A; TCGA heat map 
shown). We called this the folate cluster. GSEA cross-vali-
dated the enrichment of the folate cluster in one dataset with 
the gene signature of the folate cluster in another dataset 
(Fig. 5 B). In addition, differential analysis for enrichment in 
KEGG canonical pathway signatures in the folate cluster ver-
sus other samples provided highly correlated results between 
the TCGA LAML and the Wouters et al. (2009) datasets 
(Fig. 5 C and Table S2). Thus, the folate cluster has consistent 
genomic and functional profiles across the primary AML data-
sets. Although MTH FD2 expression is high across all AML 
samples, the folate cluster had higher expression of MTH FD2 
(Fig. 5 D). Additionally, it was enriched in genes that correlate 
with MTH FD2 signatures, a BET inhibitor (JQ1) signature 
in AML cell lines, and with a MYC target signature as defined 
by Zeller et al. (Zeller et al., 2003; based on two-tailed Fisher 
test with a cutoff P < 0.05; Fig. 5 A and Table S3). Compre-
hensive association tests in each of the two primary tumor 
datasets found that samples in the folate cluster were enriched 
for CEB PA and FLT3-ITD mutations (Fig. 5 A, TCGA data 
shown, and Fig. 5 E). MTH FD2 single gene expression, how-
ever, was not consistently associated with recurrent AML 
gene mutations, including CEB PA and FLT3-ITD.
We next probed data from an shRNA screen of 56,903 
shRNAs directed against 14,222 genes, out of which 11,946 
genes have complete measurements (Achilles v2.4.3), per-
formed in 216 cancer cell lines, including 17 AML cell 
lines (Cowley et al., 2014). AML cell lines characterized 
by a FLT3-ITD mutation, MV4-11 and MOLM-13, were 
more sensitive to MTH FD2 suppression compared with 
other AML cell lines (Fig. 6, A and B), and suppression of 
MTH FD2 was in the top 5% of dependencies in each 
individual cell line (Fig.  6  C). In support of this obser-
vation, suppression of MTH FD2 in FLT3-ITD positive 
cell lines significantly increased cell death compared with 
FLT3 wild-type cell lines (Fig.  6  D). Thus, targeting of 
MTH FD2 may be particularly efficacious in AML char-
acterized by FLT3-ITDs.
To further study the effect of MTH FD2 suppression 
in a FLT3-ITD model, we extended our testing of MTH FD2- 
directed hairpins to a human AML orthotopic xenograft 
model, MV4-11. Here, MV4-11 cells were labeled with 
luciferase (MV4-11-LucNeo) infected with vectors bear-
ing MTH FD2-directed shRNAs (shMTH FD2_3 and 
shMTH FD2_5), and selected with puromycin. Knockdown 
of MTH FD2 was then confirmed by Western immunoblot-
ting before injection by tail vein into NSG mice (Fig. 6 E). 
Loss of MTH FD2 impaired leukemia progression of this 
MV4-11 orthotopic xenograft, as measured in vivo by biolu-
minescence (Fig. 6 E) and by flow cytometry (Fig. 6 F), and 
prolonged mouse survival (Fig. 6 G).
evaluated 9 d after infection with MTH FD2-targeting shRNAs. Shown are representative flow graphs from three different experiments. (F) Bar graphs depict-
ing differentiation score (weighted summed score) for three AML cell lines after MTH FD2 knockdown. Error bars represent ± SD of eight replicates. *, P < 0.05; 
***, P = 0.0002 using Mann-Whitney test, relative to control per cell line. Shown is a representative of two separate experiments.
1291JEM Vol. 213, No. 7
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MYC regulates the mitochondrial 
one-carbon folate pathway
We next turned to the Connectivity Map, a large database 
profiling the effects of small molecules and shRNAs on gene 
expression in cancer cell lines (http ://www .lincscloud .org) 
to evaluate whether suppression of other proteins can mimic 
MTH FD2 suppression. We used a gene expression signature of 
MTH FD2 suppression that was previously developed within 
the Connectivity Map and found that MYC knockdown 
scored as one of the top shRNA connections to the expression 
profile of MTH FD2 knockdown (Fig.  7  A and Table S4). 
MYC is a key regulator of cellular pathways and has been shown 
to control mitochondrial serine hydroxymethyltransferase 2 
(SHMT2; Nikiforov et al., 2002). However, whether MYC 
directly binds and controls expression of genes in the 
mitochondrial one-carbon folate pathway in AML has not 
been reported. We first evaluated MYC knockdown with 
two unique doxycycline-inducible miR30 shRNAs. MYC 
suppression resulted in a decrease in MTH FD2 transcript 
and protein, in addition to decreased expression of other 
enzymes associated with the mitochondrial one-carbon 
folate pathway, such as MTH FD 1-like (MTH FD1L) and 
SHMT2 (Fig. 7, B and C). JQ1 is a small molecule inhibitor 
of the BET-bromodomain–containing protein BRD4 and 
decreases MYC expression in AML cells (Zuber et al., 2011). 
Treatment of AML cell lines with JQ1 recapitulated the 
findings of MYC suppression using shRNA (Fig. 7, D and 
E). Additionally, mononuclear cells from two primary patient 
AML samples were extracted and treated with 1 µM JQ1 for 
24 h. qRT-PCR showed a decrease in MYC, MTH FD2, and 
the other evaluated mitochondrial proteins of the one-carbon 
folate pathway (Fig. 7 F).
We next used publicly available chromatin immuno-
precipitation sequencing (ChIP-Seq; Lin et al., 2012) and 
ENC ODE data to assess whether MYC binds at promoter 
regions of SHMT2, MTH FD1L, and MTH FD2. MYC binds 
at SHMT2, MTH FD2, and MTH FD1L promoters in Burkitt 
lymphoma, small cell lung cancer, glioblastoma multiforme, 
and multiple myeloma cell lines (Table S5; data for MTH FD2 
shown). MYC also binds at the MTH FD2, SHMT2, and 
MTH FD1L promoters of K562, a chronic myeloid leukemia 
cell line. Interestingly, the relative signal score is highest in 
K562 cells compared with H1-hESC (normal human em-
bryonic stem cells) and GM12878 (normal B lymphocytes) 
for MTH FD2 (Table S5). To evaluate whether MYC directly 
binds to promoters of genes of the mitochondrial one-car-
bon folate pathway in AML, we treated two AML cell lines, 
MOLM-14 and U937, with JQ1 and performed ChIP-quan-
titative PCR (ChIP-qPCR). After MYC immunoprecipita-
tion and qPCR, we found a significant decrease in MYC 
binding at MTH FD2, MTH FD1L, and SHMT2 promoters 
(Fig. 7 G). Collectively, these data suggest that the expression 
of genes involved in mitochondrial one-carbon folate metab-
olism is directly regulated by MYC.
Suppression of MTH FD2 causes metabolic alterations
Loss of MTH FD2 has been reported to result in glycine 
auxotrophy in murine fibroblasts (Patel et al., 2003). In line 
with this observation, suppression of MTH FD2 in two AML 
cell lines resulted in increased dependence on exogenous 
glycine (Fig. 8 A). We next measured production of labeled 
glycine from [U-13C3]serine over time using Gas Chroma-
tography-Mass Spectrometry (GC-MS) in media after MTH FD2 
suppression in MOLM-14 cells. MTH FD2 suppression led to 
an inability to produce glycine from serine (Fig. 8 B). Mea-
surement of intracellular metabolite levels confirmed an ac-
cumulation of serine and a decrease in intracellular glycine in 
MOLM-14 cells after MTH FD2 suppression (Fig. 8 C).
MTH FD2 catalyzes conversion of methylene tetrahy-
drofolate to formyl tetrahydrofolate via its dehydrogenase and 
cyclohydrolase activities. Formyl THF is converted to formate 
by MTH FD1L (Christensen and Mackenzie, 2008). Thus, 
formate supplementation might be expected to rescue MTH FD2 
suppression. Addition of 1 and 10  mM formate to media, 
however, did not rescue the viability effect of MTH FD2 
suppression in the MOLM-14 cell line (Fig. 8 D). Thus, the 
metabolic alterations leading to decreased AML cell growth 
with suppression of MTH FD2 are likely distinct from any 
reduction in formate production.
We next turned to an unbiased approach with metabolic 
profiling using Liquid Chromatography and Mass Spectros-
copy (LC-MS) to discover other metabolic alterations caused 
by MTH FD2 suppression. MOLM-14 and U937 cells were 
profiled after MTH FD2 suppression for 3 d. Suppression of 
Figure 4. MTH FD2 knockdown impairs leukemia establishment and progression in vivo. (A) Graph depicting growth in mice of U937-LucNeo cells 
infected with MTH FD2-directed shRNA versus LacZ (shControl). Bioluminescence was quantified as a measure of disease burden. Data are represented as 
a mean ± SEM of six mice per cohort. Western blot shows MTH FD2 levels at the time of injection of cells. P = 0.0008 using two-way ANO VA. (B) RNA was 
isolated from mouse MLL-AF9 cells, and Mthfd2 suppression was confirmed at time of cell injection. (C) Graph showing percentage of MLL-AF9–positive 
cells in mouse peripheral blood with or without Mthfd2 suppression. Shown is mean percentage ± SD for four mice. (D) Kaplan-Meier curve showing 
overall survival of mice with MLL-AF9 leukemia after suppression of MTH FD2 versus shControl (n = 4 per group). P < 0.03 calculated using log-rank test. 
(E) FACS plot showing induction of shRNA with doxycycline treatment (DsRed+/Venus+). (F) qRT-PCR showing relative amount of MTH FD2 after treatment 
with doxycycline. Bar graphs represent mean value ± SD for four replicates. P < 0.01, Mann-Whitney test. (G) Graph depicting growth of U937-LucNeo cells 
transduced with a doxycycline-inducible TRM PVIR vector containing either a scrambled miR30-shRNA (shCT) or shRNAs directed against MTH FD2 after 
injection into Nude mice and treatment with doxycycline to induce shRNA expression. Graphs represent mean bioluminescence ± SD for six mice per group. 
P < 0.05, Mann-Whitney test at week 5. (H) Kaplan-Meier curves showing overall survival of mice (n = 6 per group). P = 0.037 for shMTH FD2_1 and P = 
0.014 for shMTH FD2_2, calculated using log-rank test.
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Figure 5. ssGSEA identifies a folate cluster and establishes FLT3-ITD as a sensitivity marker for MTH FD2 suppression. (A) Heat map of ssGSEA 
projection for the primary AML tumor dataset from TCGA on the collection of KEGG canonical pathways. Cluster annotation bar depicts consensus clusters 
and their degree of enrichment in the one-carbon folate pathway. Samples in the folate cluster are highlighted in red. Other annotation bars highlight 
enrichment in signatures of MTH FD2, JQ1 effect, MYC targets, mutations associated with folate cluster, and FAB subtypes. For each of these signatures, the 
enrichment was computed per primary tumor by applying the ssGSEA method. The level of enrichment was assessed based on the absolute cut-off value 
1 applied to the ssGSEA z-scores: samples with ssGSEA z-scores ≥1 were labeled as significantly highly enriched in the signature and highlighted black, 
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MTH FD2 significantly depleted TCA cycle intermediates 
and cholesterol esters (Fig. 8, E and F). Additionally, there was 
up-regulation of sphingomyelin and triglyceride production 
(Fig.  8  E). A metabolic hallmark of naive embryonic stem 
cells is their ability to maintain pluripotency by using high 
levels of α-ketoglutarate with alterations in the succinate to 
α-ketoglutarate ratio, leading to changes in the stemness state 
of the cell (Carey et al., 2015). In AML cells, MTH FD2 sup-
pression led to an increase in the succinate to α-ketoglutarate 
ratio (Fig. 8 G) consistent with the increase in differentiation 
and decrease in stem cell signatures in AML cell lines per-
turbed by MTH FD2-directed shRNAs.
DIS CUS SION
In the last two decades, little advancement has been made in 
cure rates of AML, the most common cause of acute leukemia 
in adults. Thus, new therapies are needed for this disease. We 
set out to identify pathways that are consistently suppressed 
in AML with AML-directed drugs. The one-carbon folate 
pathway emerged at the intersection of genes significantly 
altered by these agents. Given the recent interest in this path-
way in cancer metabolism, we focused on its role in AML, 
with a specific study of MTH FD2, a mitochondrial enzyme 
involved in folate metabolism that is consistently down-regu-
lated across all of the probed datasets and highly differentially 
expressed in cancer compared with normal cells.
One-carbon folate metabolism is a complex network 
involving several amino acids, nucleotide synthesis, support 
of cellular methylation reactions via methionine and s-ade-
nosylmethionine production, and support of lipid metabo-
lism (Locasale, 2013). In the cytoplasm, serine is converted to 
formate by the trifunctional enzyme MTH FD1. In the mi-
tochondria, the dehydrogenase and cyclohydrolase activities 
are performed by MTH FD2, whereas the synthetase activities 
are performed by MTH FD1L (Christensen and Mackenzie, 
2008). Recent studies have led to an increased appreciation 
for metabolic reprogramming and its contribution to can-
cer pathogenesis. Although there is a long history of targeting 
folate metabolism in the treatment of patients with cancer, 
the precise role of glycine/serine and one-carbon folate me-
tabolism in mitochondria and its potential contribution to 
cancer metabolic reprogramming, have only recently come 
to light. Glycine metabolism has been correlated with rates 
of cancer cell proliferation, and antagonizing glycine synthe-
sis through suppression of SHMT2 was shown to decrease 
cancer cell growth (Jain et al., 2012). In the same year, glycine 
decarboxylase and other glycine/serine-related enzymes, in-
cluding SHMT2, were found to promote cellular transforma-
tion and tumorigenesis in lung cancer models (Zhang et al., 
2012). Additionally, SHMT2 was found to drive glioma cell 
proliferation in the presence of ischemia, making the cells 
sensitive to inhibition of the glycine cleavage system (Kim et 
al., 2015). In an analysis of differentially expressed mRNA in 
cancer tissues, Nilsson et al. (2014) identified enzymes of the 
one-carbon folate pathway to be among the most differen-
tially expressed metabolic enzymes in cancer compared with 
normal cells, with MTH FD2 ranking at the top of the list. In 
addition, MTH FD2 expression correlated with poor survival 
in patients with breast cancer (Liu et al., 2014; Nilsson et al., 
2014). The combination of its high expression in cancer cells 
and restricted pattern of expression in normal tissues made 
MTH FD2 an attractive target for further exploration.
The exact mechanistic role of MTH FD2 in cancer is 
still a topic of debate. The mitochondrial one-carbon folate 
pathway and MTH FD2 have been suggested to provide mito-
chondrial-derived one-carbon units in the form of formate for 
purine biosynthesis (Christensen and Mackenzie, 2008). How-
ever, we could not rescue the effects of MTH FD2 suppression 
in AML cell lines with the addition of up to 10 mM formate 
concentrations, a similar observation to that of Nilsson et al. 
(2014). More recently, several publications supported the role 
of mitochondrial one-carbon metabolism in redox homeosta-
sis and NAD PH production (Fan et al., 2014; Ye et al., 2014). 
Fan et al. (2014) demonstrated a decrease in the NAD PH/
NADP+ ratio with MTH FD2 knockdown in HEK293T cells, 
and Ye et al. (2014) demonstrated a decrease in the NAD PH/
NADP+ ratio with SHMT2 knockdown only in hypoxic con-
ditions in neuroblastoma cells (Fan et al., 2014; Ye et al., 2014). 
Given that MTH FD2 is an NAD+ dependent enzyme, we fo-
cused on measuring NAD+/NADH ratio in AML cells after 
MTH FD2 suppression and did not find a consistent difference 
in this ratio in the AML cell line setting (unpublished data), 
whereas samples with ssGSEA z-scores ≤−1 were labeled as significantly low enriched in the signature and highlighted blue. Samples that did not pass the 
significance cut-off were labeled as not significantly enriched and highlighted white. (B) GSEA cross-validation tests for consistency of the folate cluster 
signature across primary AML tumor datasets. Each GSEA plot shows enrichment of the folate cluster phenotype in one dataset with the gene signature 
of the folate cluster in the other dataset. P < 0.0001; P = 0.003, computed using the permutation test for gene set enrichment implemented in the GSEA 
v2.0.14 platform. (C) Scatter plot of differential KEGG pathway enrichment SNR scores for samples in the folate cluster versus all other samples in TCGA 
LAML versus Wouters et al. (2009) datasets. The regression line indicates the Pearson correlation coefficient R = 0.94 (P < 0.001, computed using the R v3.2 
cor.test function, implemented in the library stats). Red dots correspond to KEGG pathways positively enriched in both TCGA LAML and Wouters et al. folate 
clusters. Blue dots correspond to KEGG pathways negatively enriched in both TCGA LAML and Wouters et al. folate clusters. The yellow highlighted dot cor-
responds to the one-carbon folate pathway. The complete descriptions of the KEGG pathways and of the differentially enriched scores in the two datasets 
are provided in Table S2. (D) Box plots showing MTH FD2 expression in the folate cluster, shown in red in A, compared with the nonfolate cluster, shown in 
dark blue in Panel A for TCGA and Wouters et al. datasets. P = 0.0008 for TCGA and P = 0.0014 for Wouters et al., Welch-corrected two-tailed Student’s t 
test. (E) Two-dimensional barplots depicting the results of two-tailed Fisher exact tests for enrichment of the folate cluster with FLT3-ITD mutations. *, P < 
0.05, two-tailed Fisher’s exact test.
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possibly due in part to the fact that the whole cell NAD+/
NADH ratio is dominated by cofactor levels in the cytosol, 
and MTH FD2 knockdown is expected to affect the mito-
chondrial NAD+/NADH ratio. Tracing compartmentalized 
NAD PH metabolism (Lewis et al., 2014) was also not possi-
ble because MTH FD2 suppression resulted in a profound de-
crease in cellular α-ketoglutarate levels. In fact, levels of all TCA 
cycle metabolites were suppressed, potentially because loss of 
MTH FD2 alters mitochondrial redox metabolism. Decreases 
in TCA intermediates were also observed with impaired mi-
tochondrial NAD+/NADH metabolism (Sullivan et al., 2015).
Despite a fall in all TCA cycle intermediates, there was a 
significant increase in the succinate to α-ketoglutarate ratio in 
MOLM-14 cells after MTH FD2 suppression, a possible met-
abolic mechanism for the inhibition of stem cell signatures 
and the induction of differentiation of AML cells. Recent 
work from Carey et al. (2015) suggests that naive embryonic 
stem cells maintain an elevated α-ketoglutarate to succinate 
ratio that promotes pluripotency through histone and DNA 
demethylation. It will be important, in future studies, to 
explore the effects of MTH FD2 suppression on the epigen-
etic state of AML cells.
Figure 6. FLT3-ITD is a marker of sensitivity for MTH FD2 suppression. (A) Ranking of MTH FD2 depletion score across 216 cell lines in a shRNA screen. 
Red dots represent FLT3-ITD–mutated AML cell lines. Blue dots represent other AML cell lines. Gray dots represent non-AML cell lines. (B) Box plots showing 
mean MTH FD2 dependency for AML cell lines. P < 0.05, Mann-Whitney test. (C) MTH FD2 ranks as 191 out of 11,946 (top 1.6%) dependency in the MV4-11 
cell line and 575 out of 11,946 (top 4.8%) in the MOLM-13 cell line. MTH FD2 is shown in red among all shRNA rankings for each individual cell line. (D) 
Suppression of MTH FD2 causes significant apoptosis in FLT3-ITD mutant cell lines. Shown is percent Annexin V–positive cells per cell line with shControl, 
shMTH FD2_3, or shMTH FD2_5. Data show a representative experiment from at least three individual experiments. (E) Graph depicting growth in mice of 
MV4-11-LucNeo cells infected with MTH FD2-directed shRNA versus LacZ (shControl). Bioluminescence was quantified as a measure of disease burden. Data 
are represented as a mean ± SEM of four mice per cohort. P < 0.05 at Week 4, Mann-Whitney test. Western blot shows MTH FD2 level at time of injection of 
cells. (F) FACS plot showing percent of human CD45+ cells in bone marrow in mice injected with MV4-11-LucNeo cells, 16 d after injection. (G) Kaplan-Meier 
curve showing overall survival of mice with MV4-11-LucNeo cells after suppression of MTH FD2 versus shControl (n = 5 per group). *, P < 0.05 relative to 
control, calculated using log-rank test.
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The limited expression of MTH FD2 in normal adult 
tissues, and high level of expression in cancer cells, may in part 
be explained by the regulation of MTH FD2 expression by 
MYC. MYC is a master regulator of cell proliferation, affect-
ing regulation of immortality, cell cycle progression, genetic 
instability, apoptosis and metabolism (Dang, 2012). In cancer, 
pathological activation of MYC commonly plays a key role in 
disease pathogenesis. MYC stimulates expression of many mi-
tochondrial genes that are encoded in the nucleus and even 
regulates mitochondrial biogenesis itself (Li et al., 2005). In 
the Connectivity Map, an MTH FD2 knockdown signature 
recapitulated changes in expression associated with knock-
down of MYC. Using publicly available ChIP-Seq data, we 
identified MYC binding at the promoter sites of SHMT2, 
MTH FD2, and MTH FD1L and preferential binding of MYC 
at MTH FD2 promoter sites in cancer cells compared with 
nonmalignant cells. We then performed ChIP-qPCR and 
confirmed this finding in AML cell lines. Previously, MYC 
has been implicated in controlling the one-carbon folate 
pathway, especially in the presence of hypoxia (Nikiforov et 
al., 2002; Ye et al., 2014), though this has not been previously 
studied in AML. In future studies, it may also be informa-
tive to perform metabolic profiling with MYC suppression 
by BET bromodomain inhibitors alone and in combination 
with MTH FD2-specific suppression.
Based on the expression level of MTH FD2 in hemato-
poietic stem cells, MTH FD2 suppression would be expected to 
have some bone marrow toxicity. Indeed, we observed highly 
variable suppression of colony formation in normal CD34+ 
cells with MTH FD2-directed shRNAs in four independent 
experiments (unpublished data). The variability likely reflects 
the challenges of transducing CD34+ cells, experimental dif-
ferences in levels of knockdown, and variability in donor 
CD34+ cells. However, given the low expression of MTH 
FD2 in other adult tissues, our expectation is that an MTH 
FD2 inhibitor would be more selective than other inhibitors 
of the one-carbon folate pathway, such as methotrexate, on 
normal adult tissues. Accordingly, MTH FD2 suppression has 
minimal effect on the growth of 293T or Ba/F3 cells.
Predictors of response are essential to successful can-
cer drug development. FLT3-ITD emerged as a biomarker 
of response to MTH FD2 suppression at the intersection of 
an shRNA screen and in silico query of genome-wide ex-
pression profiling of primary patient AML cells. FLT3-ITD 
is a gain-of-function mutation and is one of the most com-
mon alterations in AML, accounting for ∼20% of adult AML 
(Marcucci et al., 2011). AML with FLT3-ITD is characterized 
by higher rates of relapse, leading to poor overall survival of as 
low as 25% (Thiede et al., 2002). Inhibitors of FLT3 have re-
cently been reported to improve survival in combination with 
chemotherapy in patients with FLT3 mutant AML (Stone et 
al., 2015). It will thus be important to test FLT3 inhibitors in 
combination with MTH FD2 suppression in future studies. 
Although the precise mechanism for increased sensitivity to 
MTH FD2 suppression in FLT3-ITD AML is uncertain, one 
might speculate that the increased production of reactive ox-
ygen species by internal tandem duplications of FLT3 may 
render greater sensitivity (Sallmyr et al., 2008; Godfrey et al., 
2012; Stanicka et al., 2015).
This work argues that MTH FD2 inhibitors are needed 
to further examine targeting this enzyme as a novel treatment 
strategy in AML. All of the previously published work and 
the studies presented here have relied on shRNA-directed 
suppression of MTH FD2, a limitation to the studies. It will 
be critical to validate that enzymatic inhibition of the target 
reproduces the effects seen with loss of total protein. More-
over, small-molecule probes will empower the mechanistic 
dissection of this target as the kinetics of shRNA suppression 
are slower than acute inhibition with a compound.
In summary, this study defines a critical role for MTH FD2 
in AML and nominates FLT3-ITD as a biomarker of re-
sponse to MTH FD2 suppression. With differential expression 
of MTH FD2 in cancer tissues, and its preferential expres-
sion in embryonic tissues, targeting of MTH FD2 may offer 
a superior therapeutic window for inhibition in comparison 
with drugs in current use that target the one-carbon folate 
metabolism more broadly.
MAT ERI ALS AND MET HODS
Cell culture and primary AML cells
U937, HL-60, and 293T cells were purchased from ATCC. 
Ba/F3 cells were purchased from DSMZ. THP-1, MV4-11, 
Figure 7. MYC controls one-carbon folate pathway. (A) MTH FD2 knockdown signature was used to probe the Connectivity Map for targets that mimic 
the effect of MTH FD2 knockdown. Red highlights 97 shRNAs that are significantly enriched (CMap consensus score > 0.90) and blue shows shRNAs that 
are anticorrelated (CMap consensus score < −0.90). Red line represents relative position of MYC hairpin enrichment. (B) Two AML cell lines were transduced 
with two different doxycycline inducible miR30 shRNAs targeting MYC (shMYC_2 and shMYC_3). A scrambled miR30 shRNA was used as control (shCT). 
Gene expression of MYC, MTH FD2, MTH FD1L, and SHMT2 was measured by qRT-PCR. Shown are the mean ± SD of four replicate measurements. (C) Western 
blot of the treated cell lines confirms a reduction in target protein after doxycycline treatment. (D) Western blot of two AML cell lines treated with 1 µM 
JQ1 showing a time-dependent decrease in proteins of the mitochondrial one-carbon folate pathway. (E) Three AML cell lines were treated with 1 µM JQ1 
versus vehicle and qRT-PCR was performed. *, P < 0.05, Mann-Whitney test. (F) Mononuclear cells extracted from two AML patient samples were treated 
with 1 µM JQ1 for 24 h. Target gene expression was evaluated by qRT-PCR. Shown is the relative mean expression ± SD of 4 replicate measurements. HEX 
IM, a target known to increase with JQ1 treatment, was used as a control. *, P < 0.05, Mann-Whitney test. (G) ChIP-qPCR was performed on two AML cell 
lines after treatment with 1 µM JQ1 for 48 h. Shown is fold enrichment over input. Error bars represent four calculations based on two replicates. Binding 
at NPM1 promoter region was measured as a positive control and binding at ZIC3 promoter region as a negative control. Data show a representative ex-
periment of two individual experiments.
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Figure 8. Suppression of MTH FD2 increases glycine dependence, depletes intermediates of the TCA cycle and alters the succinate to α-keto-
glutarate ratio. (A) MTH FD2 knockdown using shRNA resulted in an increased dependence on exogenous glycine in two AML cell lines. Graphs depict cell 
number as measured by trypan blue exclusion. Shown are the means ± SD of 3 replicates. (B) MTH FD2 suppression results in failure to produce glycine from 
serine in MOLM-14 cells. After MTH FD2 suppression, MOLM-14 cells were cultured in glycine free media in the presence of [U-13C3]Serine (all three carbons 
labeled with 13C). Media was extracted at the time points shown and M+2 glycine (both carbons labeled with 13C) was measured by GC-MS. (*) represents 
P < 0.05 at each time point for hairpins shMTHD2_3 and shMTH FD2_5 relative to shControl, Wilcoxon rank sum test. Shown are the mean ± SD of three 
replicates. (C) Amounts of intracellular serine and glycine (total ion counts, TIC) from MOLM-14 cells cultured in complete media for 24 h after MTH FD2 
suppression, as measured by GC-MS, and then normalized to norvaline as an internal standard. Shown are the mean ± SD of 3 replicates. (*) represents 
P < 0.05 for hairpins shMTHD2_3 and shMTH FD2_5 relative to shControl, Wilcoxon rank sum test with continuity correction. (D) Suppression of MTH FD2 
affects growth of AML cells that are not rescued by formate supplementation in the MOLM-14 cell line. Viability measured by Trypan blue exclusion over 
a time course with MTH FD2-directed shRNA versus control shRNA. Shown are the mean ± SD of three replicates. (E) MSEA showing metabolic pathways 
differentially altered by MTH FD2 suppression. Shown is data for MOLM-14 cell line. Blue dots represent pathways that are significantly depleted and red 
dots represent pathways that are significantly enriched (P < 0.05, permutation test in MSEA). (F) Heat map showing changes in glycolysis intermediates, 
lactate, and TCA cycle intermediates. Metabolites were selected if they were significantly (P < 0.05, Student’s t test) decreased in MOLM-14 cell line. 
(G) Ratio of intracellular succinate to α-ketoglutarate (a.u.) in MOLM-14 cells cultured in complete media for 24 h after MTH FD2 suppression, as measured 
by GC-MS. Shown is the mean ± SEM of three replicates. *, P < 0.05 for hairpins shMTHD2_3 and shMTH FD2_5 relative to shControl, Wilcoxon rank sum 
test with continuity correction.
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and MOLM-14 cells were provided by Scott Armstrong. 
MOLM-13 cells were provided by Benjamin Ebert. All cell 
lines were maintained in RPMI 1640 (Cellgro) supplemented 
with 1% penicillin/streptomycin (PS; Cellgro) and 10% FBS 
(Sigma-Aldrich) at 37°C with 5% CO2. The 293T cells were 
maintained in Dulbecco’s modified Eagle’s medium (Invitro-
gen) supplemented with 10% FBS (Invitrogen) and 1% PS. 
Ba/F3 cells were maintained in RPMI-1640 supplemented 
with 1% PS, 10% FBS, and IL-3 (PeproTech).
Primary patient AML blasts were collected from pe-
ripheral blood or bone marrow aspirate after obtaining 
informed consent under Dana-Farber Institute Internal 
Review Board–approved protocols. Mononuclear cells 
were isolated using Ficoll-Paque Plus (GE Healthcare), and 
red blood cells were lysed (eBioscience). AML blasts from 
patients were maintained in SFEM (Stemcell Technolo-
gies) with SCF, FLT3L, IL-3, IL-6, and GCSF (PeproTech). 
For drug treatment of primary AML cells, RPMI-1640 
with PS and FBS were used.
Murine MLL-AF9–expressing leukemia cells were 
obtained from a quaternary bone marrow transplant model 
from Benjamin Ebert’s laboratory. Cells were maintained 
in SFEM media (Stemcell Technologies) with murine IL-3, 
IL-6, and SCF cytokines (PeproTech).
Compounds
JQ1 was provided by J. Bradner (Dana-Farber Cancer Insti-
tute, Boston, MA). JQ1 was diluted in DMSO.
Plasmids and shRNA constructs
Oligonucleotides encoding human and murine shRNAs 
were obtained from The RNAi Consortium (TRC) and 
were cloned into pLKO.1 vectors as described previously 
(Moffat et al., 2006). Sequences targeted by each of these 
hairpins are listed in Table S6. shRNA constructs targeting 
MTH FD2 with miR30 expression cassettes were designed 
and delivered via a TRM PVIR vector as previously described 
(Puissant et al., 2014). For virus production, 12 µg of the 
aforementioned vector with 6 µg pCMV-GAG/POL and 
pCMV-VSVG (for retroviral infection of human cells) or 6 
µg pCMV8.9 and pCMV-VSVG (for lentiviral infection of 
human or murine cells, respectively) packaging vectors were 
transfected into the 293 packaging cell line using X-treme-
GENE 9 (Roche), and the resulting viral supernatants were 
harvested as previously described (Banerji et al., 2012). The 
lentiviral viruses were concentrated using PEG-it Virus Pre-
cipitation Solution (SBI Biosciences).
Morphological evaluation
Cellular morphology was evaluated on day 7 after infection 
of AML cell lines. Cytospins were prepared and stained with 
May-Grunwald Giemsa (Sigma-Aldrich) to evaluate cellu-
lar morphology. Images were acquired by light microscopy 
under oil at 1,000× magnification with a Bx41 microscope 
(Olympus) and SPOT software.
Viability assays
For assessment of growth, cells were plated in triplicate and 
manually counted with Trypan blue exclusion on the in-
dicated days. Additionally, viability was evaluated using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega). 
Luminescence was measured using FLUOstar Omega from 
BMG Labtech. For the glycine deprivation assay, cells were 
washed in PBS, and then resuspended in custom-made 
glycine-free RPMI media (GIB CO) with or without glycine. 
Glycine solution was added at 140  µM. Dialyzed FBS was 
used to minimize the contribution of glycine from FBS.
Flow cytometry
The cell surface marker Cd11b (IM0530U; Beckman Coulter) 
was measured at day 7 after infection with the pLKO.1 vec-
tors. For cell cycle analysis, AML cells were harvested at the 
indicated time points, washed, and fixed in ethanol, and 
then resuspended in 49 µg/ml propidium iodide (Sigma- 
Aldrich) and 100 µg/ml of RNase A (QIA GEN). Cell death 
was assessed using flow cytometric analysis of Annexin V and 
propidium iodide staining according to the manufacturer’s in-
structions (eBioscience). Samples were analyzed on a Fortessa 
analyzer. Data analysis was completed using ModFit Software 
for cell cycle analysis and FlowJo software for the remainder 
of flow cytometry data.
Immunoblotting
Cells were lysed in Cell Signaling Lysis Buffer (Cell Signal-
ing Technology), as previously reported (Banerji et al., 2012), 
and resolved by gel electrophoresis using Novex 4–12% Bis-
Tris Gel (Invitrogen), transferred to nitrocellulose membranes 
(Bio-Rad Laboratories), and blocked for 1  h in 5% BSA 
(Sigma-Aldrich). Blots were incubated in primary antibody 
to MTH FD2 (ab56772; Abcam), MYC (5605; Cell Signal-
ing Technology), MTH FD1L (16113–1-AP; Protein Tech), 
SHMT2 (155230; Abcam), Actin (MS-1295-P; Neomarkers), 
and Vinculin (ab18058; Abcam), followed by the secondary 
antibodies anti–rabbit HRP (NA9340V; GE Healthcare) or 
anti–mouse HRP (NA9310V; GE Healthcare). Bound anti-
body was detected using Western Lightning Chemilumines-
cence Reagents (Perkin Elmer).
Methylcellulose colony-forming assay
U937, MOLM-14, and THP-1 cells were infected with 
shRNAs directed against LacZ (shControl) or MTH FD2. 
Puromycin was added for selection after 2 d. After 3 d of selec-
tion, cells were counted by Trypan blue exclusion, and 3 × 104 
cells were plated at 1:10 (vol/vol) in methylcellulose (Clona-
Cell-TCS Medium) with 1% PS and 1 µg/ml puromycin.
Primary patient AML blasts were obtained as described 
above. These cells were maintained in StemSpan SFEM 
(StemCell Technologies) medium supplemented with 20 ng/
ml IL-3 (PeproTech), 20 ng/ml IL-6 (PeproTech), 20 ng/ml 
GCSF (PeproTech), 100 ng/ml FLT3-Ligand (PeproTech), 
and 100 ng/ml SCF (PeproTech). They were serially trans-
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duced with concentrated lentivirus, with shRNA directed 
against LacZ or MTH FD2 by two rounds of spin infection 
(6  h at 1,800  g) each at 24-h intervals using plates coated 
with 50 µg/ml retronectin (Takara Bio Inc.) before a 48-h 
antibiotic selection. Viable cells (1.5 × 103 cells/ml) were then 
plated into semisolid methylcellulose medium (MethoCult; 
StemCell Technologies) supplemented with selection antibi-
otics and cytokines. After at least 10 d, the colony number was 
evaluated after MTT staining of the colonies (R&D Systems).
Gene expression–based high-throughput screening (GE-HTS)
The GE-HTS assay, using ligation-mediated amplification 
(LMA) and a fluorescent bead-based detection, was performed 
as previously described (Banerji et al., 2012). The weighted 
summed score was used to compare differentiation signature 
induction, as previously described (Banerji et al., 2012).
In vivo studies
U937 or MV4-11 cells were transduced with pMMP-Luc-
Neo retrovirus and selected with neomycin at 1 mg/ml. 
U937-LucNeo or MV4-11-LucNeo cells were transduced 
with lentiviruses encoding shRNAs targeting MTH FD2 
(shMTH FD2_3 and shMTH FD2_5) or LacZ (shControl). 
Transduced cells were selected with 1 µg/ml puromycin for 
48 h, and viable cells were counted using trypan blue exclu-
sion. For U937-LucNeo cells, 5 million cells per mouse were 
injected via tail vein into 7-wk-old NSG mice (The Jack-
son Laboratory). For MV4-11-LucNeo cells, 1.5 million cells 
per mouse were injected via tail vein into 6–8-wk-old NSG 
mice (The Jackson Laboratory). Leukemia burden was serially 
assessed using noninvasive bioluminescence imaging by in-
jecting mice with 75 mg/kg i.p. d-Luciferin (Promega), anes-
thetizing them with 2–3% isoflurane, and imaging them on an 
IVIS Spectrum (Caliper Life Sciences). A standardized region 
of interest (ROI) encompassing the entire mouse was used to 
determine total body bioluminescence, with data expressed 
as photons/s/ROI (ph/s/ROI). Additionally, leukemia bur-
den was assessed in the MV4-11-LucNeo model using flow 
cytometry analysis of the percent of human CD45+ leukemic 
cells within mice bone marrow at 16 d after injection.
The U937-LucNeo study was conducted under the 
auspices of protocols approved by the Dana-Farber Can-
cer Institute Animal Care and Use Committee. The MV4-
11-LucNeo study was reviewed and approved by the 
Massachusetts Institute of Technology Committee on Ani-
mal Care (Cambridge, MA).
U937 cells were transduced with the pMMP-LucNeo 
retrovirus and selected with neomycin at 1 mg/ml. After se-
lection, luciferase-expressing U937 cells were transduced with 
retroviral doxycycline-inducible miR30-shRNA constructs, 
either control or constructs expressing two MTH FD2-tar-
geting shRNAs. 1.5 million cells were subsequently injected 
via tail vein into 6–8-wk-old nude mice (The Jackson Labo-
ratory) and mice were imaged weekly on an IVIS Spectrum 
(Caliper Life Sciences) to assess the bioluminescence level. 
At a significant detection level of bioluminescence (∼7–10 d 
after cell injection), mice were treated daily by i.p injection 
with 20 µg/ml doxycycline to quickly induce hairpin ex-
pression, and drinking water was supplemented with 1 mg/
ml doxycycline and 5% sucrose throughout the experiment.
MLL-AF9-DsRed L-GMP cells were transduced with 
lentivirus encoding shRNAs targeting Mthfd2 (shMthfd2_A1, 
shMthfd2_A2, and shMthfd2_A4) or LacZ (shControl) and 
selected with 1 µg/ml puromycin for 24 h before tail vein in-
jection into sublethally irradiated 6-wk-old C57BL/6 recipi-
ent mice. Leukemia burden was assessed using flow cytometry 
analysis of the percent of DsRed-positive MLL-AF9 leukemic 
cells within mice bone marrow at 7 and 12 d after injection. 
The Massachusetts Institute of Technology Committee on An-
imal Care reviewed and approved these mouse experiments.
RNA extraction and qRT-PCR
RNA was extracted from cells with an RNeasy kit (QIA 
GEN). Probes for qRT-PCR were obtained from Applied 
Biosciences and are listed in Table S7. Data were collected in 
technical quadruplicate, analyzed using the ΔΔCT method, 
and plotted as the percentage of transcript compared with the 
negative control condition.
ChIP-qPCR
ChIP-qPCR was performed as previously described by Bernt 
et al. (2011). In brief, cross-linking was performed in cell cul-
ture medium containing 1% formaldehyde with gentle rota-
tion for 5 min in room temperature. Fixation was stopped by 
the addition of glycine (125 mM final concentration). Fixed 
cells were washed twice in ice-cold PBS, and then resuspended 
in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM and Tris-
HCl, pH 8.1, supplemented with Complete mini-protease in-
hibitor cocktail [Roche]). Chromatin was sheared to ∼200-bp 
fragments by Covaris ultrasonication. MYC (Santa Cruz Bio-
technology, Inc.) antibody was used for ChIP. Precipitates were 
washed sequentially with ice cold low-salt wash (0.1% SDS, 1% 
Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, and 
150 mM NaCl), high salt wash (0.1% SDS, 1% Triton-X-100, 
2 mM EDTA, 20 mM Tris-HCl, pH 8.1, and 500 mM NaCl), 
LiCl wash (0.25 M LiCl, 1% IGE PAL CA-630, 1% deoxycho-
lic acid, 1 mM EDTA, and 10 mM Tris-HCl, pH 8.1), and TE 
wash (1 mM EDTA and 10 mM Tris-HCl, pH 8.1) and eluted 
in elution buffer (1% SDS and 0.1 M NaHCO3). Eluted DNA 
fragments were analyzed by qPCR. Primers used for ChIP-
qPCR are as follows: MTH FD2 (forward: 5′-TCG GAC TTC 
GCT TAC GTT TAA TAA-3′ reverse: 5′-GCC ACT GGC TGT 
CTG TTG AG-3′), MTH FD1L (forward: 5′-GTG GGC GTG 
GGC ATC TC-3′ reverse: 5′-GGC GCG ATT GCA TCA GA-
3′), SHMT2 (forward: 5′-TGT CCT CAT TCT GGC GAT 
CA-3′ reverse: 5′-TCC CCT AAT GCC ACG TGA AA-3′), 
NPM1 (forward: 5′-GTT GGA GCG GGT AGA TGCA-3′ re-
verse: 5′-GCA CGC GAG GTA AGT CTA CGT-3′), and ZIC3 
(forward: 5′-CCT TTC CGA CTA CGG CAC TTC-3′ reverse: 
5′-TCA TGG GTG GGA CGT TCTG-3′).
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Global metabolite profiling
Metabolite profiles of lipid and polar metabolite extracts from 
cultured cells and spent media were measured using several 
liquid chromatography tandem mass spectrometry (LC-MS) 
methods. Lipids were extracted from cells cultured in 6-well 
plates using 800 µl of isopropanol and from 10 µl of media 
using 190 µl of isopropanol. Lipid extracts were directly an-
alyzed (10 µl) using BEH C8 chromatography method op-
erated on Nexera X2 U-HPLC (Shimadzu) coupled to an 
Exactive Plus Orbitrap mass spectrometer (Thermo Fisher 
Scientific), as previously described (Mascanfroni et al., 2015). 
Polar metabolites were extracted from cells cultured in 6-well 
plates using 800 µl of 80% methanol and analyzed using two 
LC-MS methods and from 10 µl of media using 190 µl of iso-
propanol. Lipid extracts were directly analyzed using a BEH C8 
chromatography method operated on Nexera X2 U-HPLC 
(Shimadzu) coupled to an Exactive Plus Orbitrap mass spec-
trometer (Thermo Fisher Scientific) as previously described 
(Mascanfroni et al., 2015). Polar metabolites were extracted 
from cultured cells using 800 µl of 80% methanol and from 
media using either four volumes of 80% methanol for nega-
tive ion mode analyses or nine volumes of 74.9:24.9:0.2 vol/
vol/vol acetonitrile/methanol/formic acid containing stable 
isotope-labeled internal standards (valine-d8, Isotec; and phe-
nylalanine-d8, Cambridge Isotope Laboratories) for positive 
ion mode analyses. Using previously described hydrophilic 
interaction liquid chromatography (HIL IC) methods, nega-
tive ion mode analyses of polar metabolites, including cen-
tral metabolites, were conducted using an AQU ITY UPLC 
(Waters) coupled to a 5500 QTR AP (SCI EX; Townsend et 
al., 2013), and positive ion mode profiles of polar metabo-
lites, including amino acids, were acquired using a Nexera 
X2 U-HPLC (Shimadzu) coupled to a Q Exactive Orbitrap 
(Thermo Fisher Scientific; Mascanfroni et al., 2015).
Measuring succinate to α-ketoglutarate ratio
Polar metabolites were extracted from cells after MTH FD2 
knockdown for 4 d using 60% methanol. Metabolites were 
back extracted with an equal volume of chloroform, dried, 
and then analyzed by gas chromatography mass spectrometry 
(GC-MS) as previously described (Lewis et al., 2014).
Measuring intracellular serine and glycine
After MTH FD2 knockdown for 4 d, cells were cultured for 
24 h in full media and polar metabolites were extracted and 
analyzed by GC-MS as described for the measurement of the 
succinate to α-ketoglutarate ratio.
Stable isotope tracing
Glycine production from serine was measured by culturing 
MTH FD2 knockdown cells in glycine-free media contain-
ing 0.4 mM [U-13C3]serine (Cambridge Isotope Laborato-
ries) supplemented with 10% dialyzed FBS for 24 h. Polar 
metabolites from spent media were extracted using ace-
tone (300 µl acetone, 20 µl media), dried, and analyzed by 
GC-MS, as described for the measurement of the succinate 
to α-ketoglutarate ratio.
Computational biology methods
Development of a core differentiation signature for AML. A 
core differentiation signature for AML was created by inter-
secting the lists of genes down-regulated by five prodifferen-
tiation small molecules in studies for which gene expression 
data are available at the National Center for Biotechnology 
Information’s Gene Expression Omnibus (GEO) database: 
HL-60 cell line treated with 1,25-dihydroxy Vitamin D3 (Vi-
tamin D), PMA, and all-trans retinoic acid versus DMSO 
(Stegmaier et al., 2004; GEO accession no. GSE995; Affymetrix 
HG-U133A); THP-1 cell line treated with JQ1 versus DMSO 
(Zuber et al., 2011; GEO accession no. GSE29799; Affymet-
rix HuGene-1.0 ST Array), and MV4-11 and MOLM-13 cell 
lines treated with the DOT1L inhibitor EPZ004777 versus 
DMSO (Daigle et al., 2011; GEO accession no. GSE29828; 
Affymetrix HG-U133_Plus_2).
Data processing. Each expression dataset was log2 transformed 
and all probe sets with the maximum log2 expression across 
samples less than four were filtered. After filtering, the num-
ber of probe sets remained for each dataset included: 21,620 
out of the 22,215 (GSE995), 26,672 out of the 32,321 
(GSE29799), and 26,422 out of the 54,613 (GSE29828). 
Each filtered dataset was then collapsed to nonredundant 
genes with distinct HUGO symbols by assigning to each 
gene the probe set with maximum average intensity. The col-
lapsed datasets were described by 12,891 genes (GSE995), 
20,201 genes (GSE29799), and 11,727 genes (GSE29828).
Comparative marker analysis. The individual genes that were 
differentially down-regulated between samples treated with a 
differentiation agent versus DMSO were identified by apply-
ing the Comparative Marker Selection module from the 
GenePattern v3.8.1 platform (Reich et al., 2006). A 2-sided 
signal-to-noise ratio (SNR) test followed by 1,000 permuta-
tions of phenotype labels was performed for each analysis. 
The settings for the SNR parameters were log-transformed-
data: yes, complete: no, balanced: no, smooth p-values: yes. 
A permutation P ≤ 0.05, a FDR(BH) ≤ 0.05, accounting for 
multiple hypothesis testing, and an absolute fold-change (FC) 
≥1.5 served as a cutoff for significant genes. The genes in the 
core differentiation signature were selected based on two cri-
teria: mean FC of expression between DMSO and each dif-
ferentiation agent across all datasets ≥1.5 and significant fold 
change of expression ≥ 1.5 (P ≤ 0.05; FDR[BH] ≤ 0.05) 
between DMSO and a differentiation agent in at least four 
out of the five experiments.
Overlap of the core differentiation signature with the collec-
tion of KEGG canonical pathways. The core differentiation 
signature was analyzed for significant overlap with the collec-
tion of 186 canonical KEGG pathways (Kanehisa et al., 2014) 
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available from the Molecular Signature Database v4.0 (Subra-
manian et al., 2005). Computations were performed by ap-
plying the hypergeometric test implemented in the MSigDB 
module Investigate Gene Sets, with the significance cutoff of 
10−4 for the FDR q-value.
MTH FD2 knockdown (MTH FD2 KD) RNA-Seq data analysis. 
MOLM-14 cells were transduced with lentivirus encoding 
shRNAs targeting MTH FD2 (shMTH FD2_5 hairpin, 
denoted M5) and control (LacZ, shControl). RNA from six 
samples, biological duplicates (LacZ1, LacZ2; M5-1, M5-2), 
and a technical replicate (LacZ3, M5-3) were sequenced as 
50+50 bp paired-end reads using Illumina TruSeq strand 
specific library. The total number of reads for individual 
samples ranged from 44 to 48 Mb. Quality control tests for 
the unmapped reads were performed using the FAS TQC 
software (http ://www .bioinformatics .babraham .ac .uk /
projects /fastqc /). The reads were aligned to the GRCh37 
(hg19) GEN CODE v17 annotated human reference genome 
by using Bowtie v1.0.0 (Langmead et al., 2009). The average 
percentage of uniquely mapped reads in the aligned data 
were 85.11%, with a standard deviation <5%. FPKM scores 
for genes were computed based on the RSEM R software 
package (Li and Dewey, 2011). Expression data were estimated 
as log2(FPKM). The significance of the differential expression 
between the LacZ and M5 phenotypes was estimated by 
using the EBSeq method implemented in the EBSeq R 
library (Leng et al., 2013), based on the significance cutoff (P 
< 0.05) for the posterior probability. The RNASeq data for 
the MTH FD2 KD experiment is available for download from 
GEO under accession no. GSE81062.
MTH FD2 KD GSEA. The GSEA software (v2.0.14; Mootha et 
al., 2003; Subramanian et al., 2005) was used to identify asso-
ciations of the MTH FD2 KD phenotype with hematopoietic 
lineage differentiation gene signatures based on the Differen-
tiation Map data (Novershtern et al., 2011), available in the 
GEO database as GSE24759. The gene signatures for hemato-
poietic lineage differentiation were created as described in 
Novershtern et al. (2011) based on the Student’s t test for 
differential expression and corrected for multiple hypotheses 
with the Bonferroni correction (significance cutoffs, P = 
0.05 and FDR = 0.05).
GSEA analyzes the list of differentially expressed genes 
between two experimental classes, ranked by the correlation 
with the class distinction. The goal of GSEA is to identify 
groups of genes sharing common biological function (gene 
sets) that are distributed at the top or at the bottom of the 
ranked list of differentially expressed genes. GSEA assigns to 
each gene set an enrichment score (ES) calculated as a run-
ning sum statistic by walking down across the ranked list of 
differentially expressed genes, increasing the sum when en-
countering genes in the gene set and decreasing it when en-
countering genes not in the gene set. The significance of the 
ES is estimated based on a permutation p-value and adjusted 
for multiple hypotheses testing through FDR. Gene sets with 
an FDR q-value ≤ 0.25 and a nominal P ≤ 0.05 were con-
sidered significant. The gene ranking metric in the weighted 
enrichment score was the two-sided SNR, and the p-values 
were calculated using 1,000 permutations of the phenotype.
MTH FD2 Connectivity Map (CMap) gene signature. The 
MTH FD2 hairpin knockdown signature (MTH FD2-trt.sh) 
was downloaded from the LIN CS-CMap/L1000 database 
(Lamb et al., 2006; Lamb, 2007). The Library of Integrated 
Cellular Signatures (LIN CS)-Connectivity Map (LIN CS-
CMap) is a catalog of gene expression data collected from 
human cells treated with chemical compounds and genetic 
reagents. The LIN CS is a National Institutes of Health pro-
gram (U54 HG006093) that supports the generation of pro-
files across multiple cell and perturbation types, as well as assay 
read-outs. The L1000 assay is a novel mRNA expression pro-
filing technique based on a reduced representation of the ge-
nome whereby a collection of 1,000 selected transcripts are 
monitored and used to computationally infer the remainder 
of the transcriptome. This approach utilizes Luminex beads 
and provides a high-throughput (384-well based), low-cost 
method that can enable large-scale profiling efforts.
The CMap MTH FD2 trt-sh signature was de-
fined based on five hairpins (TRCN0000290804, 
TRCN0000036550, TRCN0000036551, TRCN0000036553, 
and TRCN0000290805) in >90 experiments across a panel of 
cell lines (HEPG2, VCAP, HCC515, HT29, A549, A375, MCF7, 
PC3, HA1E, and NPC). The genetic perturbation connections 
of the CMap MTH FD2-trt.sh signature were queried with the 
Gene Digest Look Up module.
In silico identification of a Folate cluster in primary AML 
expression data. Primary human AML expression data are as 
follows: the TCGA LAML RNASeq data were created for 
179 primary AML samples obtained from adult de novo 
patients and were previously described in Cancer Genome 
Atlas Research Network (2013). Processed FPKM gene level 
data were downloaded from the TCGA GDAC website (http 
://gdac .broadinstitute .org). RPKM data were log2 
transformed and the genes expressed below the noise 
threshold RPKM < 1 across all the samples were filtered out. 
The filtered data were described by 19,796 genes identified 
through unique Human Genome Organisation (HUGO) 
names. Clinical annotation, mutation profiles, and survival 
information were available for download from Cancer 
Genome Atlas Research Network (2013) and http ://
gdac .broadinstitute .org.
Wouters AML data are as follows: gene expression pro-
filing on Affymetrix HG-U133_Plus_2 chips for 526 samples 
of de novo AML was previously described (Wouters et al., 
2009) and is available for download from the GEO repository 
under accession no. GSE14468. Expression data were log2 
transformed, and the probe sets with log2 expression below 4 
across all the samples were filtered out. The remaining probe 
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sets were collapsed to 16,593 genes described by unique 
HUGO names by selecting for each gene the probe set with 
the maximum average expression across all the samples.
ssGSEA projection of primary AML samples on collection of 
canonical KEGG pathways. ssGSEA is an unsupervised gene 
enrichment method that calculates a separate enrichment 
score for each pairing of sample and gene set, independent of 
sample phenotype labeling (Subramanian et al., 2005; Barbie 
et al., 2009). ssGSEA is implemented in the ssGSEA Projec-
tion module of GenePattern v3.9.0 (Subramanian et al., 2005; 
Barbie et al., 2009). The method is also implemented in the 
GenePrerank module of the GSEA v2.0.14 platform. The 
ssGSEA method assigns to each individual sample—repre-
sented as a genome-wide ranked list of genes—an ES with 
respect to each gene set in a given collection of pathways. 
ssGSEA provides an unsupervised representation of the gene 
expression data in the space of gene sets, and thus offers po-
tentially more biological interpretability. The ssGSEA gene 
set representation can be further analyzed with unsupervised 
or supervised machine learning and statistical tools. ES is cal-
culated as described for MTH FD2 KD GSEA analysis. A pos-
itive ES denotes a significant overlap of the signature gene set 
with groups of genes at the top of the ranked list, whereas a 
negative ES denotes a significant overlap of the signature gene 
set with groups of genes at the bottom of the ranked list. For 
each sample, the ES was further transformed into a z-score by 
subtracting the mean of the ES’s assigned to all other samples 
and by dividing the result to their standard deviation. ssGSEA 
projection on the collection of 186 KEGG canonical path-
ways, collections of MYC target gene set signatures, 
MTH FD2 signatures and JQ1 treatment effect signatures was 
applied separately to each of the primary AML transcript 
datasets–TCGA_LAML and Wouters (Cancer Genome Atlas 
Research Network, 2013). ssGSEA projection on gene set 
signatures for MTH FD2 KD, CMap MTH FD2 trt-sh, MTH 
FD2 expression z-score, JQ1 treatment (Zuber et al., 2011), 
Consensus_JQ1 signature (Puissant et al., 2014), and MYC 
target gene signatures (MSigDB c2.v04 collection) were per-
formed in each primary tumor dataset. A ssGSEA z-score cut-
off 1 was used to assess if a tumor sample is highly enriched 
in any of the gene signatures.
The associations between samples in the folate clus-
ter and samples enriched in the MTH FD2 expression 
signature, JQ1 effect, MYC target signature, or with ge-
netic or clinical covariates, were estimated based on a two-
tailed Fisher exact test.
Consensus hierarchical clustering for the identification of 
the folate cluster. Consensus hierarchical clustering based on 
the mean linking method (Monti et al., 2003), implemented 
in the R package ConsensusClustering Plus (Wilkerson and 
Hayes, 2010) was used for clustering the ssGSEA projections 
on the collection of 186 canonical KEGG pathways for each 
of the TCGA LAML and Wouters et al. (2009) datasets. Con-
sensus clustering is an unsupervised machine learning ap-
proach aimed at identifying robust groups of samples that 
remain clustered together irrespective of small stochastic per-
turbations, either in the data or in the clustering procedure. 
For a preselected number of clusters, k = 2, 3, consensus clus-
tering applies iteratively (e.g., n = 1,000 times), a clustering 
method (e.g., hierarchical clustering) specific to perturbed 
instances of the data (e.g., after subsampling 80% of samples 
and/or 80% of genes), and then splits the data into k clusters 
based on an agreement matrix that describes the robustness of 
the clustering solutions along the N iterations. The agreement 
matrix is defined as a matrix with rows and columns corre-
sponding to samples that record for each pair of samples the 
fraction of times (out of the N iterations) the samples are 
clustered together. The agreement matrix is further clustered 
into k consensus clusters. For each consensus cluster, the core 
is defined by the subset of samples in the cluster with high 
pairwise agreement scores (e.g., above the cutoff 0.75), and 
the border is defined by the samples with low pairwise agree-
ment scores (e.g., below the cutoff 0.25). The overall quality 
of a clustering solution is measured by silhouette scores de-
fined based on the pairwise similarity of samples within each 
cluster and by the pairwise dissimilarity of samples within 
different clusters. The optimal number k of clusters in the data 
are assessed based on the maximum quality score for various 
clustering solutions (k = 2, 3, etc.) estimated by a consensus 
cumulative distribution function (Monti et al., 2003). In each 
of the primary AML datasets, the samples in the two core 
clusters identified by applying the consensus clustering ap-
proach at a level k = 2, were found to show very high mean 
pairwise agreement scores (>0.90) and to remain unsplit as 
core groups in any subsequent clustering into k = 3, 4, 5 clus-
ters. In each primary AML dataset, one of these two core 
clusters was found to be significantly enriched in the one-car-
bon pool folate, purine metabolism, and pyrimidine metabo-
lism pathways, and it was called the folate cluster. Gene 
signatures for the folate cluster were created separately in the 
TCGA LAML and the Wouters et al. (2009) expression data-
sets based on the top 300 genes that are significantly up-reg-
ulated (or down-regulated) in the folate cluster versus the 
other cluster (absolute FC of expression ≥ 1.5; P ≤ 0.05; 
FDR[BH] ≤ 0.05). Heat map projections were created 
using the GENE-E software.
shRNA screen analysis
The screen was performed from the Achilles v2.4.3 dataset 
(Cowley et al., 2014) derived from next-generation sequenc-
ing deconvolution of 216 cell lines from 22 cancer types, with 
an shRNA library of 56,903 barcoded shRNAs in lentiviral 
vectors targeting 14,222 genes, out of which 11,946 genes 
have complete measurements. 
Dependency z-scores for each gene were identified 
by using the previously described Analytic Technique for 
Assessment of RNAi by Similarity (ATARiS; Shao et al., 
2013). The MTH FD2 dependency z-scores across the 216 
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lines were computed based on the three MTH FD2 hair-
pins with reliable consistency scores for on-target gene 
suppression: TRCN0000290805, TRCN0000290881, and 
TRCN0000290880. The differences in MTH FD2 de-
pendency z-scores in AML-FLT3.ITD versus AML FLT3.
WT cell lines in Achilles data were evaluated based on 
the Mann-Whitney nonparametric test with the cut-off 
0.05 applied to the p-value. The genome-wide gene level 
dependency z-scores within the individual FLT3-ITD 
AML cell lines, MOLM-13 and MV4-11, were illustrated 
through waterfall barplots.
Statistics
Statistical significance was determined by Mann-Whitney, 
Wilcoxon rank test, or unpaired Student’s t test for pair-
wise comparison of groups as indicated in figure legends. 
Log-rank test was used for survival curves. Two-way ANO 
VA was used for comparisons of two or more groups 
over time. Permutation test was used for GSEA and 
MSEA statistical analysis.
Online supplemental material
Table S1 lists the 198 differentially expressed after treatment 
of AML cells with five AML-targeting agents. Table S2 lists 
the differentially enriched KEGG pathways in the folate 
cluster versus other tumors. Table S3 shows the Fisher tests 
for significant functional correlations with the folate cluster 
in the TCGA LAML and Wouters et al. (2009) datasets. Table 
S4 lists 97 genetic perturbations that are positively correlated 
with MTH FD2 suppression in the connectivity map. Table 
S5 shows analysis of MYC binding at promoter regions of 
genes of mitochondrial one-carbon folate pathway in Lin et 
al. (2012) and ENC ODE datasets. Table S6 lists the shRNAs 
used in this study. Table S7 lists the TaqMan probes used in 
this study. Online supplemental material is available at http ://
www .jem .org /cgi /content /full /jem .20151574 /DC1.
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